Vybion is a pioneering company based in Ithaca, NY, specializing in the development of Intrabodies for neurodegenerative diseases. Leveraging the power of antibody technologies, Vybion's Intrabodies target and modify intracellular events, such as protein aggregation and gene dysregulation, offering a promising disease-modifying approach to therapeutics.
With a focus on addressing unmet medical needs, Vybion has emerged as a leader in the field, receiving Orphan Drug Designation for their INT41 intrabody in the treatment of Huntington's Disease. Their innovative research and development efforts have also resulted in patent issues for novel gene therapy solutions for Huntington's and Alzheimer's Disease, further solidifying their position as a key player in the industry.
Generated from the website